Government-Owned Inventions; Availability for Licensing, 63716-63718 [E8-25566]

Download as PDF 63716 Federal Register / Vol. 73, No. 208 / Monday, October 27, 2008 / Notices Dates and Times: November 13, 2008, 8 a.m.–4:30 p.m. November 14, 2008, 8 a.m.– 4:30 p.m. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Rockville, MD 20817. Status: The meeting will be open to the public. Agenda: Agency and Bureau administrative updates will be provided. Purpose: The purpose of this meeting will be to address issues relating to the nursing faculty shortage and its impact on nurse education and practice. The objectives of the meeting are: (1) To analyze achievements toward meeting recommendations that have been suggested to address the faculty shortage put forth in the National Advisory Council on Nurse Education and Practice: Second Report to the Secretary of Health and Human Services and the Congress; (2) to examine strategies instituted to address the faculty shortage; (3) to address the academic preparation of nurse educators; and (4) to address faculty salaries and any barriers to increasing faculty salaries. During this meeting, the NACNEP council members will deliberate on the content presented and formulate recommendations to the Secretary of Health and Human Services and the Congress on the impact the faculty shortage is having on nursing education and practice. Members from professional nursing, public and private organizations will present their initiatives on addressing the nursing faculty shortage. Strategies on how to prepare nursing faculty for their role will be presented. This meeting will form the basis for NACNEP’s mandated Ninth Annual Report. For Further Information Contact: Anyone interested in obtaining a roster of members, minutes of the meeting, or other relevant information can contact Nancy DouglasKersellius, Acting Executive Secretary, National Advisory Council on Nurse Education and Practice, Parklawn Building, Room 8C–26, 5600 Fishers Lane, Rockville, Maryland 20857, telephone (301) 443–5688. Information can also be found at the following Web site: https://bhpr.hrsa.gov/ nursing/nacnep.htm. Dated: October 21, 2008. Alexandra Huttinger, Director, Division of Policy Review and Coordination. [FR Doc. E8–25568 Filed 10–24–08; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health mstockstill on PROD1PC66 with NOTICES Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for VerDate Aug<31>2005 17:13 Oct 24, 2008 Jkt 217001 licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Method of Treating and Preventing Infections in Immunocompromised Subjects With Immunostimulatory CpG Oligonucleotides Description of Technology: Primary disorders of the immune system can be divided into four categories, (1) disorders of the humoral immunity, (2) disorders of cellular immunity, (3) disorders of phagocytes, and (4) disorders of complement. In addition, there are many causes of secondary immunodeficiency such as treatment with immunosuppressive or chemotherapeutic agents, protein-losing enteropathy, and infection with a human immunodeficiency virus (HIV). Generally, immunocompromised patients are unable to mount an immune response to a vaccine or an infection in the same manner as nonimmunocompromised individuals. Opportunistic infections to which individuals infected with HIV are susceptible include bacterial infections such as salmonellosis, syphilis and neurosyphilis, tuberculosis (TB), a typical mycobacterial infection, and bacillary angiomatosis (cat scratch disease), fungal infections such as aspergillosis, candidiasis (thrush, yeast infection), coccidioidomycosis, cryptococcal meningitis, and histoplasmosis, protozoal infections such as cryptosporidiosis, isosporiasis, microsporidiosis, Pneumocystis Carinii pneumonia (PCP), and toxoplasmosis, viral infections such as Cytomegalovirus (CMV), hepatitis, herpes simplex (HSV, genital herpes), herpes zoster (HZV, shingles), human papilloma virus (HPV, genital warts, cervical cancer), Molluscum Contagiosum, oral hairy leukoplakia (OHL), and progressive multifocal leukoencephalopathy (PML), and neoplasms such as Kaposi’s PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 sarcoma, systemic non-Hodgkin’s lymphoma (NHL), and primary CNS lymphoma, among others. These opportunistic infections remain principally responsible for the morbidity and mortality associated with HIV disease. This application claims use of immunostimulatory D-type CpG oligonucleotides for the treatment of immunocompromised individuals. More specifically, the application claims use of immunostimulatory D-type CpG oligonucleotides for the treatment of individuals infected with HIV. Application: Vaccine adjuvants, production of vaccines, immunotherapeutics. Development Status: Preclinical studies have been performed; oligonucleotides have been synthesized. Inventors: Dennis Klinman (FDA/ CBER; NCI) and Daniela Verthelyi (FDA/CBER). Patent Status: U.S. Provisional Application No. 60/411,944 filed 18 Sep 2002 (HHS Reference No. E–153–2002/ 0–US–01); U.S. Patent Application No. 10/666,022 filed 17 Sep 2003 (HHS Reference No. E–153–2002/0–US–03). Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Peter A. Soukas, J.D.; 301–435–4646; soukasp@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Experimental Immunology, Immune Modulation Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, PhD at 301–435– 3121 or hewesj@mail.nih.gov for more information. Method of Treating Infectious and Inflammatory Lung Disease With Suppressive Oligonucleotides Description of Technology: Lung disease is the number three killer in America, responsible for one in seven deaths, and lung disease and other breathing problems are the number one killer of babies younger than one year old. Today, more than thirty (30) million Americans are living with chronic inflammatory lung diseases such as emphysema and chronic bronchitis. In addition, approximately one hundred and fifty thousand (150,000) Americans are affected by acute respiratory distress syndrome (ARDS) each year. Many lung diseases are associated with lung inflammation. For example, ARDS involves the rapid onset of E:\FR\FM\27OCN1.SGM 27OCN1 Federal Register / Vol. 73, No. 208 / Monday, October 27, 2008 / Notices mstockstill on PROD1PC66 with NOTICES progressive malfunction of the lungs, and is usually associated with the malfunction of other organs due to the inability to take up oxygen. The condition is associated with extensive lung inflammation and small blood vessel injury in all affected organs. ARDS is commonly precipitated by trauma, sepsis (systemic infection), diffuse pneumonia, and shock. It also may be associated with extensive surgery, and certain blood abnormalities. In many cases of ARDS and other inflammatory lung diseases, the inflammatory response that accompanies the underlying disease state is much more dangerous than the underlying infection or trauma. This application claims use of suppressive oligonucleotides to suppress lung inflammation. More specifically, the application claims use of suppressive oligonucleotides for the treatment, prevention, or inhibition of pneumonia, ARDS, and chronic bronchitis. Applications: Vaccine adjuvants, production of vaccines, immunotherapeutics. Development Status: Preclinical studies have been performed; oligonucleotides have been synthesized. Inventors: Dennis Klinman (FDA/ CBER; NCI) and Hiroshi Yamada (CBER/ FDA). Patent Status: U.S. Provisional Application No. 60/417,263 filed 08 Oct 2002 (HHS Reference Number E–183– 2002/0–US–01); U.S. Patent Application No. 10/682,130 filed 07 Oct 2003 (HHS Reference Number E–183–2002/0–US– 02). Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Peter A. Soukas, J.D.; 301–435–4646; soukasp@mail.nih.gov Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Experimental Immunology, Immune Modulation Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, PhD at 301–435– 3121 or hewesj@mail.nih.gov for more information. Use of Suppressive Oligonucleotides to Treat Uveitis Description of Technology: Uveitis is a major cause of visual loss in industrialized nations. Uveitis refers to an intraocular inflammation of the uveal tract, namely, the iris, choroids, and ciliary body. Uveitis is responsible for about ten percent (10 %) of the legal VerDate Aug<31>2005 17:13 Oct 24, 2008 Jkt 217001 blindness in the United States. Complications associated with uveitis include posterior synechia, cataracts, glaucoma and retinal edema. Suppressive CpG oligodeoxynucleotides (ODNs) are ODNs capable of reducing an immune response, such as inflammation. Suppressive ODNs are DNA molecules of at least eight nucleotides in length, where the ODN forms a G-tetrad, and has a circular dichroism value greater than 2.9. In a suppressive ODN, the number of guanosines is at least two. This application claims compositions and methods for the treatment of uveitis. Specifically, the application claims use of suppressive CpG ODNs to treat uveitis. The compositions and methods of the application can be used for the treatment of anterior, posterior and diffuse uveitis. Application: Vaccine adjuvants, production of vaccines, immunotherapeutics. Developmental Status: Preclinical studies have been performed; oligonucleotides have been synthesized. Inventors: Dennis Klinman (FDA/ CBER; NCI), Igal Gery (NEI), Chiaki Fujimoto (NEI). Patent Status: U.S. Provisional Application No. 60/569,276 filed 06 May 2004 (HHS Reference No. E–152– 2004/0–US–01); PCT Application No. PCT/US2005/015761 filed 05 May 2005, which published as WO 2005/11539 on 09 Dec 2006 (HHS Reference No. E– 152–2004/0–PCT–02); U.S. Patent Application No. 11/579,518 filed 03 Nov 2006 (HHS Reference Number E– 152–2004/0–US–03); International filings in Australia, Canada, China, Europe, India, Japan, Mexico. Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Peter A. Soukas, J.D.; 301–435–4646; soukasp@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Experimental Immunology, Immune Modulation Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, PhD at 301–435– 3121 or hewesj@mail.nih.gov for more information. Use of CpG Oligodeoxynucleotides To Induce Epithelial Cell Growth Description of Invention: Wound repair is the result of complex interactions and biologic processes. Three phases have been described in normal wound healing: Acute PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 63717 inflammatory phase, extracellular matrix and collagen synthesis, and remodeling. The process involves the interaction of keratinocytes, fibroblasts and inflammatory cells at the wound site. The sequence of the healing process is initiated during an acute inflammatory phase with the deposition of provisional tissue. This is followed by re-epithelialization, collagen synthesis and deposition, fibroblast proliferation, and neovascularization, all of which ultimately define the remodeling phase. These events are influenced by growth factors and cytokines secreted by inflammatory cells or by the cells localized at the edges of the wound. Tissue regeneration is believed to be controlled by specific peptide factors which regulate the migration and proliferation of cells involved in the repair process. Thus, it has been proposed that growth factors will be useful therapeutics in the treatment of wounds, burns and other skin disorders. However, there still remains a need for additional methods to accelerate wound healing and tissue repair. This application claims methods of increasing epithelial cell growth. The methods include administering a therapeutically effective amount of a CpG oligodeoxynucleotide (ODN) to induce epithelial cell division. Also claimed are methods of inducing wound healing. The method includes treating the wound with a CpG oligonucleotide, thereby inducing wound healing. The wound can be any type of wound, including trauma or surgical wounds. The CpG ODN can be applied systemically or locally. Application: Induction of wound healing through use of CpG oligodeoxynucleotides. Developmental Status: CpG oligonucleotides have been synthesized and preclinical studies have been performed. Inventors: Dennis Klinman and Takahashi Sato (NCI). Patent Status: U.S. Provisional Application No. 60/970,145 filed 05 Sep 2007 (HHS Reference No. E–242–2007/ 0–US–01). Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Peter A. Soukas, J.D.; 301–435–4646; soukasp@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Experimental Immunology, Immune Modulation Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or E:\FR\FM\27OCN1.SGM 27OCN1 63718 Federal Register / Vol. 73, No. 208 / Monday, October 27, 2008 / Notices commercialize methods of increasing epithelial cell growth. Please contact John D. Hewes, PhD at 301–435–3121 or hewesj@mail.nih.gov for more information. Dated: October 20, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–25566 Filed 10–24–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Notice of Closed Meetings mstockstill on PROD1PC66 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; K08, K23, K99–NEI Research Training Applications. Date: November 14, 2008. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel and Executive Meeting Center, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Samuel Rawlings, PhD, Chief, Scientific Review Branch, Division of Extramural Research National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892–9300, 301–451–2020, rawlings@nei.nih.gov. Name of Committee: National Eye Institute Special Emphasis Panel; NEI Cooperative Agreement Review. Date: November 20, 2008. Time: 3 p.m. to 5:30 p.m. Agenda: To review and evaluate cooperative agreement Applications. Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Houmam H Araj, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, NIH, 5635 Fishers Lane, Suite 1300, Bethesda, MD 20892–9602, 301–451–2020, ha50c@nih.gov. VerDate Aug<31>2005 17:13 Oct 24, 2008 Jkt 217001 Name of Committee: National Eye Institute Special Emphasis Panel; NEI Core Grants for Vision Research Review. Date: December 5, 2008. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Houmam H Araj, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, NIH, 5635 Fishers Lane, Suite 1300, Bethesda, MD 20892–9602, 301–451–2020, ha50c@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) Dated: October 17, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–25357 Filed 10–24–08; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Resident Research RFA. Date: December 8–9, 2008. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037. Contact Person: Raul A Saavedra, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, Nsc; 6001 Executive Blvd., Ste. 3208, Bethesda, MD 20892–9529, 301–496–9223, saavedrr@ninds.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: October 15, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–25626 Filed 10–24–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Meeting: Secretary’s Advisory Committee on Genetics, Health, and Society Pursuant to Public Law 92–463, notice is hereby given of the 17th meeting of the Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8 a.m. to approximately 5:30 p.m. on Monday, December 1, 2008, and 8 a.m. to approximately 3 p.m. on Tuesday, December 2, 2008, at the Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201. The meeting will be open to the public with attendance limited to space available. The meeting also will be Web cast. For most of the first day of the meeting, SACGHS will review a preliminary draft report that addresses questions about whether gene patents and certain licensing practices are affecting patient access to genetic tests. SACGHS will discuss the draft report and determine whether it is ready to be released for public comment. Later in the day, the Committee will hear presentations about diagnostic laboratory standards and technology platforms and the role they are playing in innovation of genetic technologies. On day two, the Committee will continue to discuss priority issues and future study topics and come to a final decision about its strategic study plan. As always, the Committee welcomes hearing from anyone wishing to provide public comment on any issue related to genetics, health and society. Individuals who would like to provide public comment should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at 301–496–9838 or e-mail at carrs@od.nih.gov. The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting who is in need of special assistance, such as sign language interpretation or other E:\FR\FM\27OCN1.SGM 27OCN1

Agencies

[Federal Register Volume 73, Number 208 (Monday, October 27, 2008)]
[Notices]
[Pages 63716-63718]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-25566]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Method of Treating and Preventing Infections in Immunocompromised 
Subjects With Immunostimulatory CpG Oligonucleotides

    Description of Technology: Primary disorders of the immune system 
can be divided into four categories, (1) disorders of the humoral 
immunity, (2) disorders of cellular immunity, (3) disorders of 
phagocytes, and (4) disorders of complement. In addition, there are 
many causes of secondary immunodeficiency such as treatment with 
immunosuppressive or chemotherapeutic agents, protein-losing 
enteropathy, and infection with a human immunodeficiency virus (HIV). 
Generally, immunocompromised patients are unable to mount an immune 
response to a vaccine or an infection in the same manner as non-
immunocompromised individuals.
    Opportunistic infections to which individuals infected with HIV are 
susceptible include bacterial infections such as salmonellosis, 
syphilis and neurosyphilis, tuberculosis (TB), a typical mycobacterial 
infection, and bacillary angiomatosis (cat scratch disease), fungal 
infections such as aspergillosis, candidiasis (thrush, yeast 
infection), coccidioidomycosis, cryptococcal meningitis, and 
histoplasmosis, protozoal infections such as cryptosporidiosis, 
isosporiasis, microsporidiosis, Pneumocystis Carinii pneumonia (PCP), 
and toxoplasmosis, viral infections such as Cytomegalovirus (CMV), 
hepatitis, herpes simplex (HSV, genital herpes), herpes zoster (HZV, 
shingles), human papilloma virus (HPV, genital warts, cervical cancer), 
Molluscum Contagiosum, oral hairy leukoplakia (OHL), and progressive 
multifocal leukoencephalopathy (PML), and neoplasms such as Kaposi's 
sarcoma, systemic non-Hodgkin's lymphoma (NHL), and primary CNS 
lymphoma, among others. These opportunistic infections remain 
principally responsible for the morbidity and mortality associated with 
HIV disease.
    This application claims use of immunostimulatory D-type CpG 
oligonucleotides for the treatment of immunocompromised individuals. 
More specifically, the application claims use of immunostimulatory D-
type CpG oligonucleotides for the treatment of individuals infected 
with HIV.
    Application: Vaccine adjuvants, production of vaccines, 
immunotherapeutics.
    Development Status: Preclinical studies have been performed; 
oligonucleotides have been synthesized.
    Inventors: Dennis Klinman (FDA/CBER; NCI) and Daniela Verthelyi 
(FDA/CBER).
    Patent Status: U.S. Provisional Application No. 60/411,944 filed 18 
Sep 2002 (HHS Reference No. E-153-2002/0-US-01); U.S. Patent 
Application No. 10/666,022 filed 17 Sep 2003 (HHS Reference No. E-153-
2002/0-US-03).
    Licensing Status: Available for exclusive or nonexclusive 
licensing.
    Licensing Contact: Peter A. Soukas, J.D.; 301-435-4646; 
soukasp@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute, 
Laboratory of Experimental Immunology, Immune Modulation Group, is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
this technology. Please contact John D. Hewes, PhD at 301-435-3121 or 
hewesj@mail.nih.gov for more information.

Method of Treating Infectious and Inflammatory Lung Disease With 
Suppressive Oligonucleotides

    Description of Technology: Lung disease is the number three killer 
in America, responsible for one in seven deaths, and lung disease and 
other breathing problems are the number one killer of babies younger 
than one year old. Today, more than thirty (30) million Americans are 
living with chronic inflammatory lung diseases such as emphysema and 
chronic bronchitis. In addition, approximately one hundred and fifty 
thousand (150,000) Americans are affected by acute respiratory distress 
syndrome (ARDS) each year.
    Many lung diseases are associated with lung inflammation. For 
example, ARDS involves the rapid onset of

[[Page 63717]]

progressive malfunction of the lungs, and is usually associated with 
the malfunction of other organs due to the inability to take up oxygen. 
The condition is associated with extensive lung inflammation and small 
blood vessel injury in all affected organs. ARDS is commonly 
precipitated by trauma, sepsis (systemic infection), diffuse pneumonia, 
and shock. It also may be associated with extensive surgery, and 
certain blood abnormalities. In many cases of ARDS and other 
inflammatory lung diseases, the inflammatory response that accompanies 
the underlying disease state is much more dangerous than the underlying 
infection or trauma.
    This application claims use of suppressive oligonucleotides to 
suppress lung inflammation. More specifically, the application claims 
use of suppressive oligonucleotides for the treatment, prevention, or 
inhibition of pneumonia, ARDS, and chronic bronchitis.
    Applications: Vaccine adjuvants, production of vaccines, 
immunotherapeutics.
    Development Status: Preclinical studies have been performed; 
oligonucleotides have been synthesized.
    Inventors: Dennis Klinman (FDA/CBER; NCI) and Hiroshi Yamada (CBER/
FDA).
    Patent Status: U.S. Provisional Application No. 60/417,263 filed 08 
Oct 2002 (HHS Reference Number E-183-2002/0-US-01); U.S. Patent 
Application No. 10/682,130 filed 07 Oct 2003 (HHS Reference Number E-
183-2002/0-US-02).
    Licensing Status: Available for exclusive or nonexclusive 
licensing.
    Licensing Contact: Peter A. Soukas, J.D.; 301-435-4646; 
soukasp@mail.nih.gov
    Collaborative Research Opportunity: The National Cancer Institute, 
Laboratory of Experimental Immunology, Immune Modulation Group, is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
this technology. Please contact John D. Hewes, PhD at 301-435-3121 or 
hewesj@mail.nih.gov for more information.

Use of Suppressive Oligonucleotides to Treat Uveitis

    Description of Technology: Uveitis is a major cause of visual loss 
in industrialized nations. Uveitis refers to an intraocular 
inflammation of the uveal tract, namely, the iris, choroids, and 
ciliary body. Uveitis is responsible for about ten percent (10 %) of 
the legal blindness in the United States. Complications associated with 
uveitis include posterior synechia, cataracts, glaucoma and retinal 
edema.
    Suppressive CpG oligodeoxynucleotides (ODNs) are ODNs capable of 
reducing an immune response, such as inflammation. Suppressive ODNs are 
DNA molecules of at least eight nucleotides in length, where the ODN 
forms a G-tetrad, and has a circular dichroism value greater than 2.9. 
In a suppressive ODN, the number of guanosines is at least two.
    This application claims compositions and methods for the treatment 
of uveitis. Specifically, the application claims use of suppressive CpG 
ODNs to treat uveitis. The compositions and methods of the application 
can be used for the treatment of anterior, posterior and diffuse 
uveitis.
    Application: Vaccine adjuvants, production of vaccines, 
immunotherapeutics.
    Developmental Status: Preclinical studies have been performed; 
oligonucleotides have been synthesized.
    Inventors: Dennis Klinman (FDA/CBER; NCI), Igal Gery (NEI), Chiaki 
Fujimoto (NEI).
    Patent Status: U.S. Provisional Application No. 60/569,276 filed 06 
May 2004 (HHS Reference No. E-152-2004/0-US-01); PCT Application No. 
PCT/US2005/015761 filed 05 May 2005, which published as WO 2005/11539 
on 09 Dec 2006 (HHS Reference No. E-152-2004/0-PCT-02); U.S. Patent 
Application No. 11/579,518 filed 03 Nov 2006 (HHS Reference Number E-
152-2004/0-US-03); International filings in Australia, Canada, China, 
Europe, India, Japan, Mexico.
    Licensing Status: Available for exclusive or nonexclusive 
licensing.
    Licensing Contact: Peter A. Soukas, J.D.; 301-435-4646; 
soukasp@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute, 
Laboratory of Experimental Immunology, Immune Modulation Group, is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
this technology. Please contact John D. Hewes, PhD at 301-435-3121 or 
hewesj@mail.nih.gov for more information.

Use of CpG Oligodeoxynucleotides To Induce Epithelial Cell Growth

    Description of Invention: Wound repair is the result of complex 
interactions and biologic processes. Three phases have been described 
in normal wound healing: Acute inflammatory phase, extracellular matrix 
and collagen synthesis, and remodeling. The process involves the 
interaction of keratinocytes, fibroblasts and inflammatory cells at the 
wound site. The sequence of the healing process is initiated during an 
acute inflammatory phase with the deposition of provisional tissue. 
This is followed by re-epithelialization, collagen synthesis and 
deposition, fibroblast proliferation, and neovascularization, all of 
which ultimately define the remodeling phase. These events are 
influenced by growth factors and cytokines secreted by inflammatory 
cells or by the cells localized at the edges of the wound.
    Tissue regeneration is believed to be controlled by specific 
peptide factors which regulate the migration and proliferation of cells 
involved in the repair process. Thus, it has been proposed that growth 
factors will be useful therapeutics in the treatment of wounds, burns 
and other skin disorders. However, there still remains a need for 
additional methods to accelerate wound healing and tissue repair.
    This application claims methods of increasing epithelial cell 
growth. The methods include administering a therapeutically effective 
amount of a CpG oligodeoxynucleotide (ODN) to induce epithelial cell 
division. Also claimed are methods of inducing wound healing. The 
method includes treating the wound with a CpG oligonucleotide, thereby 
inducing wound healing. The wound can be any type of wound, including 
trauma or surgical wounds. The CpG ODN can be applied systemically or 
locally.
    Application: Induction of wound healing through use of CpG 
oligodeoxynucleotides.
    Developmental Status: CpG oligonucleotides have been synthesized 
and preclinical studies have been performed.
    Inventors: Dennis Klinman and Takahashi Sato (NCI).
    Patent Status: U.S. Provisional Application No. 60/970,145 filed 05 
Sep 2007 (HHS Reference No. E-242-2007/0-US-01).
    Licensing Status: Available for exclusive or nonexclusive 
licensing.
    Licensing Contact: Peter A. Soukas, J.D.; 301-435-4646; 
soukasp@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute, 
Laboratory of Experimental Immunology, Immune Modulation Group, is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or

[[Page 63718]]

commercialize methods of increasing epithelial cell growth. Please 
contact John D. Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for 
more information.

    Dated: October 20, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E8-25566 Filed 10-24-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.